ATRA
Atara Biotherapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Strong buy
+55/100
Last price
9.75
▲ 0.35 (3.72%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
8.50
Prev close
9.40
Day high
9.79
Day low
9.05
Volume
47.60K
Market cap
$97.87M
P/E (TTM)
—
52W range
3.92 – 19.15
Day trading desk
Gap from prior close
-9.57%
Prior close 9.40
VWAP
9.56
+1.94% from price
Relative volume
0.81×
Normal
Session range
15.18%
8.50 – 9.79
Position in range
97%
Near session high
ATR (14D)
0.74
7.61% of price
Prior day high
9.63
PDH
Prior day low
8.95
PDL
Bid / ask spread
—
Quote not published
Session volume
46.69K
Avg 57.32K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+21.12%
+19.2%
1M
-0.10%
-1.3%
3M
+1.04%
-3.5%
6M
+107.01%
+88.8%
YTD
-46.10%
-60.4%
1Y
-32.34%
-48.8%
3Y
-73.65%
-155.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ATRA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+540.62K
Net buying
Buy transactions
7
866.78K shares
Sell transactions
4
326.16K shares
Net transactions
+11
Buys less sells
Sell : buy shares
0.4 : 1
Mixed
Insider-held shares
1.69M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 4, 26 | CHERRY BRIAN N Director |
BUY | 104.17K | $999.99K | Direct |
| Aug 17, 26 | NGUYEN ANHCO T Chief Executive Officer |
SELL | 5.06K | $40.88K | Direct |
| Jul 22, 26 | REDMILE GROUP, L.L.C. Unknown |
— | 195.21K | — | Indirect |
| Jun 11, 26 | CHERRY BRIAN N Director |
STOCK | 24.00K | $0 | Direct |
| Jun 9, 26 | FUST MATTHEW K. Director |
STOCK | 12.00K | $0 | Direct |
| Jun 9, 26 | HEIDEN WILLIAM K Director |
STOCK | 12.00K | $0 | Direct |
| Jun 9, 26 | CIONGOLI GREGORY AUSTIN Director and Beneficial Owner of more than 10% of a Class of Security |
STOCK | 12.00K | $0 | Direct |
| May 18, 26 | GRANT-HUERTA YANINA Officer |
SELL | 2.41K | $22.04K | Direct |
| May 18, 26 | NGUYEN ANHCO T Chief Executive Officer |
SELL | 5.24K | $47.84K | Direct |
| May 7, 26 | ECOR1 CAPITAL, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
BUY | 507.41K | $4.74M | Indirect |
| May 7, 26 | PANACEA INNOVATION LTD Beneficial Owner of more than 10% of a Class of Security |
SELL | 313.45K | $3.17M | Indirect |
| Mar 17, 26 | PANACEA INNOVATION LTD Beneficial Owner of more than 10% of a Class of Security |
CONVERSION | 259.16K | $26 | Indirect |
| Mar 9, 26 | GRANT-HUERTA YANINA Officer |
STOCK | 20.30K | $0 | Direct |
| Mar 2, 26 | GRANT-HUERTA YANINA Officer |
SELL | 2.10K | $10.69K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ADIUMENTUM CAPITAL FUND I LP |
Beneficial Owner of more than 10% of a Class of Security | — | Stock Award(Grant) |
CHERRY BRIAN N |
Director | 166.49K | Purchase |
CIONGOLI GREGORY AUSTIN |
Director and Beneficial Owner of more than 10% of a Class of Security | 1.22M | Stock Award(Grant) |
ECOR1 CAPITAL, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
HYLLENGREN ERIC J |
Chief Operating Officer | 56.23K | Sale |
NGUYEN ANHCO T |
Chief Executive Officer | 132.78K | Sale |
PANACEA INNOVATION LTD |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
PANACEA VENTURE |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
REDMILE GROUP, L.L.C. |
Unknown | — | Conversion of Exercise of derivative security |
TOUCHON PASCAL |
Director | 77.95K | Stock Award(Grant) |
Fundamentals
Market cap$97.87M
Enterprise value$97.87M
Revenue (TTM)$6.19M
Gross profit$4.66M
EBITDA$-11.06M
Net income$-16.69M
EPS (TTM)$-1.35
Free cash flow$-12.52M
Total cash$9.87M
Total debt$9.88M
Book value / share$-3.92
Shares outstanding10.04M
Float4.62M
Short % of float5.50%
Dividend yield0.00%
Beta (5Y)0.22
Valuation & profitability ratios
Trailing P/E—
Forward P/E6.31
PEG ratio—
Price / sales—
Price / book—
EV / revenue15.80
EV / EBITDA-8.85
Gross margin75.27%
Operating margin-627.46%
Profit margin-269.42%
Return on equity—
Return on assets-24.14%
Debt / equity—
Current ratio1.98
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $120.77M | $128.94M | $8.57M | $63.57M | -6.3% |
| Operating revenue | $120.77M | $128.94M | $8.57M | $63.57M | -6.3% |
| Cost of revenue | $21.21M | $21.01M | $8.89M | $0 | +1.0% |
| Gross profit | $99.56M | $107.93M | -$313.00K | $63.57M | -7.8% |
| Research & development | $37.45M | $151.48M | $224.78M | $272.53M | -75.3% |
| Selling, general & admin | $26.25M | $39.89M | $50.91M | $71.55M | -34.2% |
| Total operating expense | $63.70M | $191.37M | $275.69M | $344.09M | -66.7% |
| Operating income | $35.86M | -$83.44M | -$276.01M | -$280.51M | +143.0% |
| Net interest income | -$3.11M | -$2.50M | $141.00K | $2.69M | -24.1% |
| Pre-tax income | $32.72M | -$85.42M | -$276.11M | -$228.29M | +138.3% |
| Tax provision | $31.00K | -$12.00K | $15.00K | $12.00K | +358.3% |
| Net income | $32.69M | -$85.40M | -$276.13M | -$228.30M | +138.3% |
| Net income to common | $32.69M | -$85.40M | -$276.13M | -$228.30M | +138.3% |
| Basic EPS | 2.61 | -11.41 | -65.19 | -56.00 | +122.9% |
| Diluted EPS | 2.57 | -11.41 | -65.19 | -56.00 | +122.5% |
| EBIT | $36.51M | -$80.80M | -$270.83M | -$227.92M | +145.2% |
| EBITDA | $38.63M | -$75.75M | -$266.00M | -$222.26M | +151.0% |
| Basic shares | 12.54M | 7.49M | 4.24M | 4.08M | +67.5% |
| Diluted shares | 12.72M | 7.49M | 4.24M | 4.08M | +69.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $8.48M | $25.03M | $25.84M | $92.94M | -66.1% |
| Cash & short-term investments | $8.48M | $42.50M | $51.73M | $242.82M | -80.0% |
| Accounts receivable | $1.25M | $1.48M | $34.11M | $40.22M | -15.5% |
| Inventory | $0 | $10.65M | $9.71M | $1.59M | -100.0% |
| Total current assets | $12.21M | $64.89M | $101.87M | $295.08M | -81.2% |
| Property, plant & equipment | $7.14M | $41.10M | $58.79M | $74.32M | -82.6% |
| Total assets | $20.23M | $109.10M | $165.50M | $376.42M | -81.5% |
| Total current liabilities | $14.92M | $134.57M | $142.23M | $78.92M | -88.9% |
| Total debt | $10.38M | $43.83M | $57.87M | $71.70M | -76.3% |
| Total liabilities | $58.74M | $206.38M | $264.74M | $249.78M | -71.5% |
| Retained earnings | -$2.02B | -$2.05B | -$1.97B | -$1.69B | +1.6% |
| Shareholder equity | -$38.50M | -$97.28M | -$99.23M | $126.64M | +60.4% |
| Working capital | -$2.71M | -$69.68M | -$40.36M | $216.16M | +96.1% |
| Net tangible assets | -$38.50M | -$97.28M | -$99.23M | $126.64M | +60.4% |
| Shares issued | 7.32M | 5.86M | 4.26M | 3.84M | +25.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $32.69M | -$85.40M | -$276.13M | -$228.30M | — | +138.3% |
| Depreciation & amortisation | $2.12M | $5.05M | $4.83M | $5.65M | — | -58.1% |
| Stock-based compensation | $9.75M | $27.00M | $45.39M | $53.84M | — | -63.9% |
| Change in working capital | -$104.73M | -$30.96M | $15.34M | -$61.47M | — | -238.3% |
| Operating cash flow | -$50.94M | -$68.72M | -$192.98M | -$270.43M | — | +25.9% |
| Capital expenditure | — | -$246.00K | -$1.22M | -$4.19M | -$10.58M | — |
| Investing cash flow | $18.15M | $8.62M | $123.87M | $202.96M | — | +110.4% |
| Financing cash flow | $16.10M | $59.28M | $2.01M | $53.08M | — | -72.8% |
| Free cash flow | -$50.94M | -$68.96M | -$194.20M | -$274.62M | — | +26.1% |
| End cash position | $8.48M | $25.18M | $25.99M | $93.09M | — | -66.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $630.00K | $516.00K | $1.59M | $3.45M | $17.57M | — | +22.1% |
| Operating revenue | $630.00K | $516.00K | $1.59M | $3.45M | $17.57M | — | +22.1% |
| Cost of revenue | $191.00K | $124.00K | $104.00K | $115.00K | $554.00K | — | +54.0% |
| Gross profit | $439.00K | $392.00K | $1.49M | $3.34M | $17.02M | — | +12.0% |
| Research & development | $1.34M | $164.00K | -$223.00K | $2.92M | $7.31M | — | +720.1% |
| Selling, general & admin | $3.81M | $3.60M | $4.28M | $3.99M | $6.51M | — | +6.0% |
| Total operating expense | $5.16M | $3.76M | $4.05M | $6.91M | $13.82M | — | +37.2% |
| Operating income | -$4.72M | -$3.37M | -$2.56M | -$3.57M | $3.20M | — | -40.1% |
| Net interest income | -$113.00K | -$776.00K | -$794.00K | -$705.00K | -$829.00K | — | +85.4% |
| Pre-tax income | -$4.83M | -$4.14M | -$3.41M | -$4.28M | $2.39M | — | -16.6% |
| Tax provision | $1.00K | $0 | $0 | $28.00K | $3.00K | — | — |
| Net income | -$4.83M | -$4.14M | -$3.41M | -$4.30M | $2.39M | — | -16.6% |
| Net income to common | -$4.83M | -$4.14M | -$3.41M | -$4.30M | $2.39M | — | -16.6% |
| Basic EPS | -0.32 | -0.29 | — | -0.32 | 0.20 | 3.53 | -10.3% |
| Diluted EPS | -0.32 | -0.29 | — | -0.32 | 0.19 | 3.50 | -10.3% |
| EBIT | -$4.64M | -$3.31M | -$2.51M | -$3.37M | $3.36M | — | -40.0% |
| EBITDA | -$4.63M | -$3.29M | -$2.46M | -$3.33M | $3.60M | — | -40.8% |
| Basic shares | 15.03M | 14.08M | — | 13.56M | 12.20M | 10.76M | +6.8% |
| Diluted shares | 15.03M | 14.08M | — | 13.56M | 12.31M | 10.85M | +6.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.22M | $8.36M | $8.48M | $5.74M | $16.90M | — | -61.5% |
| Cash & short-term investments | $9.87M | $8.36M | $8.48M | $13.71M | $22.32M | — | +18.1% |
| Accounts receivable | $318.00K | $0 | $1.25M | $1.91M | $0 | — | — |
| Inventory | — | — | $0 | $0 | $0 | $0 | — |
| Total current assets | $13.53M | $12.17M | $12.21M | $18.43M | $24.77M | — | +11.1% |
| Property, plant & equipment | $6.73M | $6.93M | $7.14M | $10.85M | $11.20M | — | -3.0% |
| Total assets | $21.02M | $20.00M | $20.23M | $30.17M | $36.90M | — | +5.1% |
| Total current liabilities | $6.85M | $5.64M | $14.92M | $18.06M | $14.56M | — | +21.3% |
| Total debt | $9.88M | $10.09M | $10.38M | $16.96M | $17.67M | — | -2.1% |
| Total liabilities | $58.02M | $57.31M | $58.74M | $66.80M | $71.94M | — | +1.2% |
| Retained earnings | -$2.03B | -$2.03B | -$2.02B | -$2.02B | -$2.01B | — | -0.2% |
| Shareholder equity | -$37.00M | -$37.31M | -$38.50M | -$36.63M | -$35.04M | — | +0.8% |
| Working capital | $6.68M | $6.53M | -$2.71M | $375.00K | $10.21M | — | +2.4% |
| Net tangible assets | -$37.00M | -$37.31M | -$38.50M | -$36.63M | -$35.04M | — | +0.8% |
| Shares issued | 9.44M | 8.51M | 7.32M | 7.21M | 6.98M | — | +10.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$4.83M | -$4.14M | -$3.41M | -$4.30M | $2.39M | -16.6% |
| Depreciation & amortisation | $14.00K | $29.00K | $49.00K | $36.00K | $236.00K | -51.7% |
| Stock-based compensation | $394.00K | $749.00K | $1.52M | $1.23M | $2.80M | -47.4% |
| Change in working capital | $702.00K | -$754.00K | -$1.97M | -$7.88M | -$12.77M | +193.1% |
| Operating cash flow | -$3.34M | -$3.07M | -$5.70M | -$9.79M | -$7.32M | -8.6% |
| Investing cash flow | -$6.63M | $0 | $8.44M | -$2.42M | -$5.07M | — |
| Financing cash flow | $4.83M | $2.95M | -$3.00K | $1.05M | $15.30M | +63.5% |
| Free cash flow | -$3.34M | -$3.07M | -$5.70M | -$9.79M | -$7.32M | -8.6% |
| End cash position | $3.22M | $8.36M | $8.48M | $5.74M | $16.90M | -61.5% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.25 | -0.32 | -28.0% |
| Mar 2026 | -0.22 | — | — |
| Dec 2025 | -0.10 | -0.35 | -238.7% |
| Sep 2025 | -0.67 | -0.32 | +51.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.22 | 2 | $533.33K | -84.6% |
| Next quarter | -0.19 | 2 | $900.00K | -43.6% |
| Current year | -0.95 | 2 | $2.85M | -97.6% |
| Next year | 1.55 | 2 | $40.87M | +1,334.6% |
Analyst targets & ownership
Mean target$13.67
High target$18.00
Low target$10.00
Implied upside40.17%
Analyst count3
ConsensusBUY
Strong buy / Buy0 / 2
Hold1
Sell / Strong sell0 / 0
Held by insiders16.80%
Held by institutions57.67%
Institutions holding46
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
8.79
+10.90% from price
SMA 20
9.18
+6.20% from price
SMA 50
9.03
+7.92% from price
SMA 100
9.40
+3.75% from price
SMA 200
8.21
+18.77% from price
EMA 12
9.08
+7.38% from price
EMA 26
9.11
+6.98% from price
EMA 50
9.10
+7.12% from price
RSI (14)
57.5
Neutral
MACD (12,26,9)
-0.03
Hist 0.06
ATR (14)
0.74
7.61% of price
Realised vol 30D
64.0%
Annualised
Bollinger upper
10.36
20, 2σ
Bollinger lower
8.00
20, 2σ
50 / 200 cross
Golden
9.03 vs 8.21
Trend bias
Above 200
+18.77%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.28
More volatile than market
Correlation to SPY
0.12
Largely independent
Realised vol 30D
64.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-76.9%
Peak to trough
Max drawdown 5Y
-99.2%
Peak to trough
ATR 14
0.74
7.61% of price
Beta (reported)
0.22
5Y monthly, from filing
Short interest
Shares short
404.27K
Prior 477.27K
Change vs prior
-15.3%
Shorts covering
% of float
5.50%
Normal
% of shares out
4.03%
Against total outstanding
Days to cover
8.5
Crowded exit
Float
4.62M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 18, 26 | Freedom Broker | UPGRADE | Sell | Hold |
| May 8, 26 | Canaccord Genuity | UPGRADE | Hold | Buy |
| Jan 21, 26 | Freedom Broker | DOWNGRADE | Buy | Sell |
| Jan 13, 26 | Canaccord Genuity | DOWNGRADE | Buy | Hold |
| Dec 19, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Mar 11, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jan 22, 25 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Jan 17, 25 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Dec 20, 24 | Rodman & Renshaw | INITIATED | — | Buy |
| Nov 13, 24 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Aug 21, 24 | HC Wainwright & Co. | MAINTAINED | — | Neutral |
| Aug 16, 24 | Mizuho | UPGRADE | Neutral | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:25
Split dateJun 20, 2024
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-06-26
Offering Registrations
S-8 · 2026-06-12
Periodic Financial Reports
10-Q · 2026-05-12
Corporate Changes & Voting Matters
8-K · 2026-05-07
Corporate Changes & Voting Matters
8-K · 2026-05-01
Proxy Statements
DEFA14A · 2026-04-24
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-03-23
Headlines
Atara Biotherapeutics Reports that the Tabelecleucel Biologics License Application Has Been Resubmitted to the U.S. Food and Drug Administration
Business Wire · 7d ago
Atara Biotherapeutics: Q2 Earnings Snapshot
Associated Press · 55d ago
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress
Business Wire · 55d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.